These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Pharmacokinetics of vancomycin in continuous veno-venous hemofiltration].
    Author: Gu Q, Zhu ZH, Ge M, Ge WH.
    Journal: Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Feb; 15(2):114-6. PubMed ID: 12857476.
    Abstract:
    OBJECTIVE: To investigate the pharmacokinetics of vancomycin in continuous veno-venous hemofiltration(CVVH) in order to determine appropriate vancomycin dosing strategies for patients receiving CVVH. METHODS: The serum concentrations of vancomycin were measured by TDx and the pharmacokinetics parameters were calculated. RESULTS: The pharmacokinetics of vancomycin during CVVH was fitted with open two-compartment model. At the beginning of CVVH, the pharmacokinetic parameters were: maximum plasma concentration (Cmax)=22.18 mg/L, minimum plasma concentration attained (Cmin)=5.82 mg/L, half-life of drug (T1/2)=5.75 h, apparent volume of distribution (Vd)=21.92 L, total body clearance of drug(CL)=3.49 L/h. On the 16 d of CVVH, the pharmacokinetic parameters were Cmax=38.70 mg/L, Cmin=16.50 mg/L, T1/2=33.32 h, Vd=12.92 L, CL=0.38 L/h. CONCLUSION: CVVH can significantly augment the clearance of vancomycin in acute renal failure patients. Dosing strategies for individualization of vancomycin therapy in patients receiving CVVH are proposed. Monitoring the serum concentration during CVVH is necessary.
    [Abstract] [Full Text] [Related] [New Search]